|
1
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A national cancer data base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995. Cancer.
83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiacchio S, Lorenzoni A, Boni G, Rubello
D, Elisei R and Mariani G: Anaplastic thyroid cancer: Prevalence,
diagnosis and treatment. Minerva Endocrinol. 33:341–357.
2008.PubMed/NCBI
|
|
3
|
Paunovic IR, Sipetic SB, Zoric GV, Diklic
AD, Savic DV, Marinkovic J and Zivaljevic VR: Survival and
prognostic factors of anaplastic thyroid carcinoma. Acta Chir Belg.
115:62–67. 2015. View Article : Google Scholar
|
|
4
|
Are C and Shaha AR: Anaplastic thyroid
carcinoma: Biology, pathogenesis, prognostic factors, and treatment
approaches. Ann Surg Oncol. 13:453–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka K, Sugitani I and Fujimoto Y: A
novel chemo-radiotherapy with low-dose daily cisplatin,
5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: A
preliminary report. Jpn J Clin Oncol. 41:1074–1078. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jing C, Gao Z, Wang R, Yang Z, Shi B and
Hou P: Lenvatinib enhances the antitumor effects of paclitaxel in
anaplastic thyroid cancer. Am J Cancer Res. 7:903–912.
2017.PubMed/NCBI
|
|
7
|
Stege A, Priebsch A, Nieth C and Lage H:
Stable and complete overcoming of MDR1/P-glycoprotein-mediated
multidrug resistance in human gastric carcinoma cells by RNA
interference. Cancer Gene Ther. 11:699–706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Monden N, Abe S, Hishikawa Y, Yoshimura H,
Kinugasa S, Dhar DK, Tachibana M and Nagasue N: The role of
P-glycoprotein in human gastric cancer xenografts in response to
chemotherapy. Int J Surg Investig. 1:3–10. 1999.PubMed/NCBI
|
|
9
|
Prieto-Vila M, Takahashi RU, Usuba W,
Kohama I and Ochiya T: Drug resistance driven by cancer stem cells
and their niche. Int J Mol Sci. 18:E25742017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zito G, Richiusa P, Bommarito A, Carissimi
E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato
M, et al: In vitro identification and characterization of
CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma
cell lines. PLoS One. 3:e35442008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heiden KB, Williamson AJ, Doscas ME, Ye J,
Wang Y, Liu D, Xing M, Prinz RA and Xu X: The sonic hedgehog
signaling pathway maintains the cancer stem cell self-renewal of
anaplastic thyroid cancer by inducing snail expression. J Clin
Endocrinol Metab. 99:E2178–E2187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carina V, Zito G, Pizzolanti G, Richiusa
P, Criscimanna A, Rodolico V, Tomasello L, Pitrone M, Arancio W and
Giordano C: Multiple pluripotent stem cell markers in human
anaplastic thyroid cancer: The putative upstream role of SOX2.
Thyroid. 23:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yun JY, Kim YA, Choe JY, Min H, Lee KS,
Jung Y, Oh S and Kim JE: Expression of cancer stem cell markers is
more frequent in anaplastic thyroid carcinoma compared to papillary
thyroid carcinoma and is related to adverse clinical outcome. J
Clin Pathol. 67:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung CW, Han KH, Seol H, Park S, Koh JS,
Lee SS, Kim MJ, Choi IJ and Myung JK: Expression of cancer stem
cell markers and epithelial-mesenchymal transition-related factors
in anaplastic thyroid carcinoma. Int J Clin Exp Pathol. 8:560–568.
2015.PubMed/NCBI
|
|
15
|
Goodell MA: Stem cell identification and
sorting using the Hoechst 33342 side population (SP). Curr Protoc
Cytom Chapter. 9:Unit9.18. 2005. View Article : Google Scholar
|
|
16
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is
expressed in a wide variety of stem cells and is a molecular
determinant of the side-population phenotype. Nat Med. 7:1028–1034.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang M, Wang Y and Zhong J: Side
population cells and drug resistance in breast cancer. Mol Med Rep.
11:4297–4302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Y, Fan Y, Qi Y, Liu D, Wu K, Wen F
and Zhao S: Side population cells separated from A549 lung cancer
cell line possess cancer stem cell-like properties and inhibition
of autophagy potentiates the cytotoxic effect of cisplatin. Oncol
Rep. 34:929–935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukaya R, Ohta S, Yamaguchi M, Fujii H,
Kawakami Y, Kawase T and Toda M: Isolation of cancer stem-like
cells from a side population of a human glioblastoma cell line,
SK-MG-1. Cancer Lett. 291:150–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou GX, Liu PP, Zhang S, Yang M, Liao J,
Yang J, Hu Y, Jiang WQ, Wen S and Huang P: Elimination of stem-like
cancer cell side-population by auranofin through modulation of ROS
and glycolysis. Cell Death Dis. 9:892018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie ZY, Lv K, Xiong Y and Guo WH:
ABCG2-meditated multidrug resistance and tumor-initiating capacity
of side population cells from colon cancer. Oncol Res Treat.
37(666–668): 670–672. 2014.
|
|
22
|
Pályi I, Péter I, Daubner D, Vincze B and
Lõrincz I: Establishment, characterization and drug sensitivity of
a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows
Arch B Cell Pathol Incl Mol Pathol. 63:263–269. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito T, Seyama T, Hayashi Y, Hayashi T,
Dohi K, Mizuno T, Iwamoto K, Tsuyama N, Nakamura N and Akiyama M:
Establishment of 2 human thyroid-carcinoma cell-lines (8305C,
8505C) bearing p53 gene-mutations. Int J Oncol. 4:583–586.
1994.PubMed/NCBI
|
|
24
|
Steel GG and Peckham MJ: Exploitable
mechanisms in combined radiotherapy-chemotherapy: The concept of
additivity. Int J Radiat Oncol Biol Phys. 5:85–91. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang M, Shan F, Zou Y, Sun X, Zhang ZR, Fu
Y and Gong T: Pharmacokinetic and pharmacodynamic study of a
phospholipid-based phase separation gel for once a month
administration of octreotide. J Control Release. 230:45–56. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumer J, Arbitrario J, Jones J, Henjarappa
N, Hoch U, Silverman J, Howlett A and Scatena C: SNS-595
potentiates the in vivo antitumor activity of carboplatin,
cisplatin, and gemcitabine in solid tumor xenografts. Molecular
Cancer Therapeutics. 6:3523S2007.
|
|
27
|
Derbel O, Limem S, Ségura-Ferlay C,
Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP
and de la Fouchardière C: Results of combined treatment of
anaplastic thyroid carcinoma (ATC). BMC Cancer. 11:4692011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seto A, Sugitani I, Toda K, Kawabata K,
Takahashi S and Saotome T: Chemotherapy for anaplastic thyroid
cancer using docetaxel and cisplatin: Report of eight cases. Surg
Today. 45:221–226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Yang WQ, Zhu H, Qian YY, Zhou L,
Ren YJ, Ren XC, Zhang L, Liu XP, Liu CG, et al: Regulation of
autophagy by miR-30d impacts sensitivity of anaplastic thyroid
carcinoma to cisplatin. Biochem Pharmacol. 87:562–570. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao L, Ren Y, Tang H, Wang W, He Q, Sun
J, Zhou X and Wang A: Deregulation of miR-222-ABCG2 regulatory
module in tongue squamous cell carcinoma contributes to
chemoresistance and enhanced metastatic potential. Oncotarget.
6:44538–44550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gibalová L, Sereš M, Rusnák A, Ditte P,
Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A and Sulová Z:
P-glycoprotein depresses cisplatin sensitivity in L1210 cells by
inhibiting cisplatin-induced caspase-3 activation. Toxicol In
Vitro. 26:435–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ceckova M, Vackova Z, Radilova H, Libra A,
Buncek M and Staud F: Effect of ABCG2 on cytotoxicity of platinum
drugs: Interference of EGFP. Toxicol In Vitro. 22:1846–1852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B and
Gao FG: Camptothecin and cisplatin upregulate ABCG2 and MRP2
expression by activating the ATM/NF-κB pathway in lung cancer
cells. Int J Oncol. 42:1289–1296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mayr C, Wagner A, Neureiter D, Pichler M,
Jakab M, Illig R, Berr F and Kiesslich T: The green tea catechin
epigallocatechin gallate induces cell cycle arrest and shows
potential synergism with cisplatin in biliary tract cancer cells.
BMC Complement Altern Med. 15:1942015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou Q, Ye M, Lu Y, Zhang H, Chen Q, Huang
S and Su S: Curcumin improves the tumoricidal effect of mitomycin C
by suppressing ABCG2 expression in stem Cell-like breast cancer
cells. PLoS One. 10:e01366942015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen G, Nicula D, Renko K and Derwahl M:
Synergistic anti-proliferative effect of metformin and sorafenib on
growth of anaplastic thyroid cancer cells and their stem cells.
Oncol Rep. 33:1994–2000. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rai U, Thrimawithana TR, Valery C and
Young SA: Therapeutic uses of somatostatin and its analogues:
Current view and potential applications. Pharmacol Ther.
152:98–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Olias G, Viollet C, Kusserow H, Epelbaum J
and Meyerhof W: Regulation and function of somatostatin receptors.
J Neurochem. 89:1057–1091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mazziotti G, Mosca A, Frara S, Vitale G
and Giustina A: Somatostatin analogs in the treatment of
neuroendocrine tumors: Current and emerging aspects. Expert Opin
Pharmacother. 18:1679–1689. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alghamdi AA, Jawas AM and Hart RS: Use of
octreotide for the prevention of pancreatic fistula after elective
pancreatic surgery: A systematic review and meta-analysis. Can J
Surg. 50:459–466. 2007.PubMed/NCBI
|
|
41
|
Macaulay VM, Smith IE, Everard MJ, Teale
JD, Reubi JC and Millar JL: Experimental and clinical studies with
somatostatin analogue octreotide in small cell lung cancer. Br J
Cancer. 64:451–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kouroumalis EA: Octreotide for cancer of
the liver and biliary tree. Chemotherapy. 47:150–161. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang CH, Tang CW, Liu CL and Tang LP:
Inhibitory effect of octreotide on gastric cancer growth via MAPK
pathway. World J Gastroenterol. 9:1904–1908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ayiomamitis GD, Notas G, Zaravinos A,
Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos
K and Kouroumalis E: Effects of octreotide and insulin on colon
cancer cellular proliferation and correlation with hTERT activity.
Oncoscience. 30:457–467. 2014. View Article : Google Scholar
|
|
45
|
Ebert M, Friess H, Beger HG and Büchler
MW: Role of octreotide in the treatment of pancreatic cancer.
Digestion. 55 Suppl 1:S48–S51. 1994. View Article : Google Scholar
|
|
46
|
Reubi JC, Chayvialle JA, Franc B, Cohen R,
Calmettes C and Modigliani E: Somatostatin receptors and
somatostatin content in medullary thyroid carcinomas. Lab Invest.
64:567–573. 1991.PubMed/NCBI
|
|
47
|
Ain KB, Taylor KD, Tofiq S and
Venkataraman G: Somatostatin receptor subtype expression in human
thyroid and thyroid carcinoma cell lines 1. J Clin Endocrinol
Metab. 82:1857–1862. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shen Y, Ren ML, Shi YH, Zhang YX and Cai
YL: Octreotide is the favorable alternative for cisplatin
resistance reversal of ovarian cancer in vitro and in nude mice in
vivo. Eur J Gynaecol Oncol. 33:584–590. 2012.PubMed/NCBI
|
|
49
|
Zhu S, Oremo JA, Li S, Zhen M, Tang Y and
Du Y: Synergistic antitumor activities of docetaxel and octreotide
associated with apoptotic-upregulation in castration-resistant
prostate cancer. PLoS One. 3:e918172014. View Article : Google Scholar
|
|
50
|
Hofland LJ, Lamberts SW and Feelders RA:
Role of somatostatin receptors in normal and tumoral pituitary
corticotropic cells. Neuroendocrinology. 92 Suppl 1:S11–S16. 2010.
View Article : Google Scholar
|
